Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17138865 | Opioid Receptor Score (OReS) from Combinatory Opioid Receptor Gene Polymorphisms | December 2020 | May 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17256695 | POLYMERASE ATTACHMENT TO A CONDUCTIVE CHANNEL | December 2020 | September 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17254302 | MOLECULAR MARKER COMBINATION LINKED TO QUANTITATIVE TRAITS OF TEA PLANT (+)-CATECHIN CONTENT | December 2020 | July 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17107699 | ROTATIONALLY SEQUESTERED TRANSLATORS | November 2020 | March 2024 | Allow | 40 | 0 | 1 | No | No |
| 17101904 | DIGITAL SEQUENCE ANALYSIS OF DNA METHYLATION | November 2020 | December 2023 | Allow | 36 | 1 | 0 | No | No |
| 17091507 | METHODS AND COMPOSITIONS FOR RISK PREDICTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF PULMONARY DISORDERS | November 2020 | January 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17086842 | GENE EXPRESSION ASSAY FOR MEASUREMENT OF DNA MISMATCH REPAIR DEFICIENCY | November 2020 | April 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17050134 | KIT, DEVICE, AND METHOD FOR DETECTING BLADDER CANCER | October 2020 | April 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17038290 | Methods for Molecularly Characterizing Cervical Cell Samples | September 2020 | April 2022 | Allow | 18 | 0 | 1 | Yes | No |
| 17040300 | METHODS AND MARKERS FOR AZOOSPERMIA CHARACTERISATION | September 2020 | January 2024 | Abandon | 39 | 0 | 1 | No | No |
| 16772617 | METHOD FOR AIDING DETECTION OF ALZHEIMER' S DISEASE | September 2020 | March 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16977477 | METHOD FOR ISOTHERMAL AMPLIFICATION OF NUCLEIC ACID USING PRIMERS TO GENERATE A TANDEM REPEAT SEQUENCE OF A TARGET GENE | September 2020 | January 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17008385 | PKD MUTATIONS AND EVALUATION OF SAME | August 2020 | January 2023 | Allow | 28 | 2 | 1 | Yes | No |
| 17006474 | MODIFIERS OF CFTR-DIRECTED THERAPY | August 2020 | August 2022 | Allow | 24 | 2 | 1 | No | No |
| 16975840 | A METHOD FOR MONITORING METABOLISM BEFORE AND AFTER EXERCISE OR INJURY USING SALIVARY MICRO-RNAS | August 2020 | December 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16971007 | METHODS OF DETERMINING RESPONSE TO TNF ALPHA BLOCKERS | August 2020 | June 2024 | Abandon | 46 | 2 | 1 | No | No |
| 16986667 | METHOD FOR DETERMINING THE LIKELIHOOD THAT A SUBJECT HAS OR WILL DEVELOP CANCER | August 2020 | October 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16643108 | HIERARCHICAL MODEL FOR DETECTING BENIGN AND MALIGNANT DEGREES OF COLORECTAL TUMORS AND APPLICATION THEREOF | June 2020 | January 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 16956806 | GENETIC MARKERS AND USES THEREFOR | June 2020 | September 2023 | Abandon | 39 | 3 | 1 | No | No |
| 16767968 | BIOMARKER PANEL AND METHODS FOR DETECTING MICROSATELLITE INSTABILITY IN CANCERS | May 2020 | March 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 16758896 | ENDOSIALIN (CD248) AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR NA�VE CD8+ T-CELLS | April 2020 | January 2023 | Allow | 33 | 3 | 1 | No | No |
| 16857490 | Novel Markers for Detecting Microsatellite Instability in Cancer and Determining Synthetic Lethality with Inhibition of the DNA Base Excision Repair Pathway | April 2020 | April 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16758082 | MCC AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR BASOPHIL GRANULOCYTES | April 2020 | April 2023 | Allow | 36 | 3 | 1 | Yes | No |
| 16758131 | PDCD1 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR PD1+ CELLS | April 2020 | November 2022 | Allow | 31 | 3 | 1 | No | No |
| 16810385 | COMPOSITIONS AND METHODS FOR CHARACTERIZING MARKER DNA FROM A SAMPLE | March 2020 | April 2023 | Abandon | 38 | 3 | 0 | No | No |
| 16644812 | NON-CODING RNAS (NCRNA) FOR THE DIAGNOSIS OF COGNITIVE DISORDERS | March 2020 | March 2023 | Allow | 36 | 3 | 1 | Yes | No |
| 16807379 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | March 2020 | December 2020 | Allow | 10 | 1 | 0 | No | No |
| 16800292 | Method for Using Gene Expression to Determine Prognosis of Prostate Cancer | February 2020 | December 2022 | Abandon | 33 | 4 | 1 | Yes | No |
| 16797733 | DIAGNOSTIC METHODS FOR INFECTIOUS DISEASE USING ENDOGENOUS GENE EXPRESSION | February 2020 | November 2021 | Allow | 21 | 2 | 1 | Yes | No |
| 16794754 | DETECTION AND CLASSIFICATION OF IMP CARBAPENEMASES USING REAL-TIME POLYMERASE CHAIN REACTION ASSAY | February 2020 | August 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16640323 | EXOSOME PROFILING FOR DIAGNOSIS AND MONITORING OF VASCULITIS AND VASCULOPATHIES INCLUDING KAWASAKI DISEASE | February 2020 | March 2023 | Allow | 37 | 3 | 1 | No | No |
| 16635233 | GENOTYPING OF SNPS TO STRATIFY CANCER RISK | January 2020 | May 2023 | Allow | 39 | 4 | 1 | Yes | No |
| 16632222 | MIRNAS AS BIOMARKERS FOR PARKINSON'S DISEASE | January 2020 | November 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16727281 | METHOD OF DIAGNOSING AND TREATING ACUTE REJECTION IN KIDNEY TRANSPLANT PATIENTS | December 2019 | February 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16720403 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | December 2019 | February 2021 | Allow | 14 | 0 | 1 | Yes | No |
| 16624469 | METHOD FOR PREDICTING THERAPEUTIC EFFECTS OF IRINOTECAN, AND KIT FOR SAME | December 2019 | March 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16623937 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS | December 2019 | December 2022 | Allow | 36 | 5 | 1 | Yes | No |
| 16623382 | METHOD FOR PREDICTING DIFFERENTIATION ABILITY OF PLURIPOTENT STEM CELL, AND REAGENT FOR SAME | December 2019 | February 2023 | Abandon | 38 | 2 | 1 | Yes | No |
| 16713760 | Methods and Compositions for Sequentially Detecting Targets | December 2019 | February 2023 | Allow | 38 | 1 | 1 | No | No |
| 16709780 | EXTRACT FROM A BODY FLUID COMPRISING A MICRO RNA | December 2019 | July 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16707584 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS | December 2019 | May 2022 | Allow | 29 | 4 | 1 | No | Yes |
| 16619946 | TWO MOLECULAR MARKERS, KITS AND APPLICATIONS FOR GLAUCOMA DIAGNOSIS | December 2019 | November 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16565443 | DIAGNOSTIC AND TREATMENT METHOD FOR ENDOMETRIAL CAVITY DISTORTING UTERINE LEIOMYOMA USING MICRORNA | November 2019 | May 2023 | Allow | 44 | 2 | 1 | No | No |
| 16678855 | Method to Predict Response to Neuropsychiatric Drugs Using Variation in the Serotonin 7 Receptor (HTR7) Gene | November 2019 | July 2022 | Allow | 32 | 2 | 0 | Yes | No |
| 16610011 | PREDICTIVE RESPONSE BIOMARKERS TO CORTICOSTEROIDS | October 2019 | October 2021 | Abandon | 24 | 1 | 0 | No | No |
| 16669181 | METHOD OF DETECTING BIO-MATERIAL | October 2019 | April 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16665731 | COMPOSITIONS COMPRISING ZDHHC1 DNA IN A COMPLEX | October 2019 | April 2023 | Allow | 42 | 4 | 0 | No | No |
| 16658754 | Method For Estimating A Risk For A Subject Suffering From Urothelial Carcinoma And Kit Thereof | October 2019 | May 2022 | Abandon | 31 | 2 | 1 | Yes | No |
| 16606315 | STRATIFICATION AND PROGNOSIS OF CANCER | October 2019 | May 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16498883 | METHODS FOR ASSESSING PREGNANCY OUTCOME | September 2019 | September 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16585876 | COMBINATION OF mRNA EXPRESSION LEVELS OF DLX1 AND HOXC6 IN URINE AS MOLECULAR MARKERS IN PROSTATE CANCER | September 2019 | July 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16579798 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR LUNG DISORDERS USING GENE EXPRESSION PROFILES FROM NOSE EPITHELIAL CELLS | September 2019 | December 2023 | Allow | 51 | 5 | 2 | Yes | No |
| 16576746 | USE OF PIRNA-54265 IN DIAGNOSIS, TREATMENT, AND PROGNOSTIC EVALUATION OF COLORECTAL CANCER | September 2019 | September 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16489597 | METHODS FOR DIAGNOSING, PROGNOSING, AND TREATING COLORECTAL CANCER USING BIOMARKER EXPRESSION | August 2019 | October 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16487852 | USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | August 2019 | November 2021 | Allow | 26 | 2 | 0 | Yes | No |
| 16487662 | METHOD OF DISTINGUISHING LIPOSARCOMA FROM NON-LIPOSARCOMA | August 2019 | June 2023 | Abandon | 46 | 2 | 1 | Yes | No |
| 16487301 | DNA METHYLATION SIGNATURES FOR DETERMINING A SURVIVAL PROBABILITY | August 2019 | February 2023 | Abandon | 42 | 3 | 1 | No | No |
| 16530353 | Method of Assessing Risk | August 2019 | December 2022 | Abandon | 41 | 1 | 0 | No | No |
| 16510800 | CANCER POLYGENIC RISK SCORE | July 2019 | August 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16510766 | ATRIAL FIBRILLATION POLYGENIC RISK SCORE | July 2019 | July 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16510817 | DIABETES POLYGENIC RISK SCORE | July 2019 | June 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16510834 | INFLAMMATORY BOWEL DISEASE POLYGENIC RISK SCORE | July 2019 | May 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16447221 | METHODS EMPLOYING CIRCULATING DNA AND MIRNA AS BIOMARKERS FOR FEMALE INFERTILITY | June 2019 | March 2020 | Allow | 9 | 1 | 1 | No | No |
| 16446255 | TYPING METHOD | June 2019 | August 2022 | Allow | 38 | 2 | 2 | Yes | No |
| 16471318 | COMPOSITIONS AND METHODS OF USING RNA FRAGMENTS | June 2019 | August 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16444881 | METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS | June 2019 | August 2020 | Allow | 14 | 2 | 1 | Yes | No |
| 16469760 | METHOD FOR DIAGNOSING MOOD DISORDER BY USING CIRCADIAN RHYTHM | June 2019 | February 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16469963 | EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF CERTAIN CANCERS | June 2019 | October 2023 | Allow | 52 | 4 | 1 | Yes | No |
| 16469820 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | June 2019 | January 2024 | Abandon | 55 | 2 | 1 | No | No |
| 16469946 | EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF OVARIAN CANCER | June 2019 | October 2023 | Allow | 52 | 4 | 1 | Yes | No |
| 16433971 | METHOD FOR IDENTIFICATION AND QUANTIFICATION OF NUCLEIC ACID EXPRESSION, SPLICE VARIANT, TRANSLOCATION, COPY NUMBER, OR METHYLATION CHANGES | June 2019 | May 2022 | Allow | 35 | 1 | 1 | No | No |
| 16427438 | FLOURESCENT PROTEIN COMPOSITION FOR DNA SEQUENCE ANALYSIS AND METHOD FOR DNA SEQUENCE ANALYSIS USING SAME | May 2019 | June 2022 | Allow | 37 | 3 | 1 | Yes | No |
| 16349414 | METHOD TO DISTINGUISH TUMOR SUPRESSIVE FOXO ACTIVITY FROM OXIDATIVE STRESS | May 2019 | September 2022 | Abandon | 40 | 2 | 1 | No | No |
| 16347180 | METHODS FOR ASSESSING RISK USING TOTAL AND SPECIFIC CELL-FREE DNA | May 2019 | February 2024 | Abandon | 57 | 4 | 1 | No | No |
| 16340371 | DETERMINING CELL TYPE ORIGIN OF CIRCULATING CELL-FREE DNA WITH MOLECULAR COUNTING | April 2019 | April 2022 | Abandon | 36 | 1 | 0 | No | No |
| 16379531 | BARRETT'S ESOPHAGUS PROGRESSION TO CANCER GENE PANEL AND METHODS OF USE THEREOF | April 2019 | May 2022 | Abandon | 37 | 1 | 1 | No | No |
| 16339692 | TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED IRAK | April 2019 | April 2024 | Abandon | 60 | 3 | 1 | No | Yes |
| 16333130 | METHOD FOR DETERMINING LIKELIHOOD OF SPORADIC COLORECTAL CANCER DEVELOPMENT | March 2019 | March 2023 | Abandon | 48 | 2 | 1 | Yes | No |
| 16288349 | METHODS AND DEVICES FOR BONE INFECTION TREATMENT SELECTION | February 2019 | October 2019 | Allow | 8 | 1 | 1 | Yes | No |
| 16282540 | Method for Using Gene Expression to Determine Prognosis of Prostate Cancer | February 2019 | September 2020 | Abandon | 19 | 2 | 0 | No | No |
| 16278200 | Method and Kit for Predicting Susceptibility to Allergic Reaction | February 2019 | July 2021 | Abandon | 29 | 1 | 1 | No | No |
| 16276479 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | February 2019 | November 2019 | Allow | 9 | 2 | 0 | No | No |
| 16274361 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND | February 2019 | May 2021 | Abandon | 27 | 3 | 1 | No | No |
| 16324365 | METHODS OF DETECTING MLH1 METHYLATION | February 2019 | December 2020 | Allow | 22 | 3 | 0 | No | No |
| 16271218 | SQSTM1 MUTATIONS IN AMYOTROPHIC LATERAL SCLEROSIS | February 2019 | June 2021 | Abandon | 29 | 1 | 1 | No | No |
| 16265398 | METHODS OF DETERMINING ENDOMETRIAL RECEPTIVITY AND USES THEREOF | February 2019 | October 2023 | Abandon | 57 | 3 | 1 | Yes | No |
| 16253860 | Mutations Associated with Cystic Fibrosis | January 2019 | August 2020 | Allow | 19 | 2 | 1 | Yes | No |
| 16213354 | DETECTION OF NUCLEIC ACIDS FROM PLATELET ENRICHED PLASMA SAMPLES | December 2018 | September 2021 | Abandon | 33 | 3 | 0 | No | No |
| 16210411 | SINGLE LABELED FLUORESCENT SMART PROBE FOR IN VITRO DETECTION | December 2018 | November 2020 | Abandon | 23 | 2 | 1 | Yes | No |
| 16210986 | METHOD FOR DETECTING SNP SITE ON SMA GENE | December 2018 | January 2022 | Allow | 38 | 3 | 1 | Yes | No |
| 16207648 | GENETIC EXPRESSION OF HLA MOLECULES TO ENHANCE IMMUNOTHERAPIES | December 2018 | August 2022 | Abandon | 45 | 3 | 1 | Yes | No |
| 16306724 | MITOCHONDRIAL DNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS | December 2018 | June 2022 | Allow | 42 | 5 | 1 | Yes | No |
| 16303937 | PORTABLE, LOW-COST PATHOGEN DETECTION AND STRAIN IDENTIFICATION PLATFORM | November 2018 | November 2021 | Allow | 36 | 1 | 1 | Yes | No |
| 16196163 | GENETIC MARKERS USED FOR IDENTIFYING BENIGN AND MALIGNANT PULMONARY MICRO-NODULES AND THE APPLICATION THEREOF | November 2018 | August 2023 | Allow | 57 | 5 | 1 | Yes | No |
| 16300987 | Methods For Identifying Clonal Mutations And Treating Cancer | November 2018 | July 2021 | Abandon | 32 | 1 | 0 | No | No |
| 16097954 | PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS | October 2018 | November 2020 | Allow | 25 | 4 | 0 | Yes | No |
| 16095334 | USE OF A MICROBIOME PROFILE TO DETECT LIVER DISEASE | October 2018 | June 2023 | Abandon | 56 | 2 | 1 | No | No |
| 16158065 | Use Of Wiskott-Aldrich Syndrome Protein (WASP) As A Biological Marker And In Vitro Method For Monitoring The Progression Of A Hematological Disease | October 2018 | October 2019 | Abandon | 12 | 2 | 0 | No | No |
| 16140437 | GENE EXPRESSION PROFILE AS AN ENDOMETRIAL RECEPTIVITY MARKER | September 2018 | October 2021 | Abandon | 37 | 1 | 1 | No | No |
| 16133234 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | September 2018 | August 2019 | Allow | 11 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HANEY, AMANDA MARIE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 5.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HANEY, AMANDA MARIE works in Art Unit 1634 and has examined 691 patent applications in our dataset. With an allowance rate of 24.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner HANEY, AMANDA MARIE's allowance rate of 24.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HANEY, AMANDA MARIE receive 2.20 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HANEY, AMANDA MARIE is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +46.3% benefit to allowance rate for applications examined by HANEY, AMANDA MARIE. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.6% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.6% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 72.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 51.7% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 66.3% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.